

June 15, 2009

**Dear Fellow Shareholders,**

In my shareholder letter released March 24<sup>th</sup> of this year, I outlined what directions digiMedical would be undertaking for 2009. Let me recap these directions for you and give you an update as to our progress.

**Quarter One Activity**

In recent months, the Company announced that it is growing its advisory board, with the most recent addition being Jason Whisenant [digiMedical.com/News](http://digiMedical.com/News). He and others like him will help expand the Company's ability to forecast future trends and marketing segments in the digital prescription industry, while at the same time improving our sales and marketing division.

Over the course of the first quarter, the Company also launched our new corporate website [www.digiMedical.com](http://www.digiMedical.com), detailing our proprietary digital prescription software. We also launched two other vital websites [www.digiRX.com](http://www.digiRX.com) and [www.digiReAuth.com](http://www.digiReAuth.com). These websites allow doctors and pharmacists to find out about our products and services and sign up via the Web. These websites leverage our software and significantly expand our ability to sell to and service the market with minimal backend manpower, resulting in a strong platform allowing for exponential sales growth.

**Quarter Two Activity**

Board member Philip Verges, CEO of NewMarket Technology (OTC: [NMKT](#)), introduced VirtualHealth (OTCBB: [VHGI](#)) and our Company. VirtualHealth has a medical practice management system software product with a large client base (for more information visit <http://www.mosonline.com>). I am pleased to announce a new, signed contract with VirtualHealth to offer our software and services in conjunction with their software to their client base of over 1,500 offices nationwide.

This is a significant move for digiMedical to increase our sales channels and our software's visibility in the market. In the third quarter, we will continue to work on this new sales channel to sign on more doctors. We plan to issue more information on this agreement in the future and we will continue to look for other large sales channels to partner with.

Additionally, in quarter three, we are planning to roll out a new version, 3.0, of our digiRX product.

IMPORTANT \ CONFIDENTIAL:

This correspondence contains information from digiMedical Solutions Corporation that may be privileged, confidential, and exempt from disclosure under applicable laws. If the reader of this message is not the intended recipient or the associate, or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately at our telephone number (817) 503-8880

## Summary

digiMedical is focused on expanding our market share through reselling our software products digiRX, digiReAuth and digiPRN Pharmacies by forging agreements with partners that have an existing client base and sales channels, like with VirtualHealth, that will significantly increase our sales and visibility in the market.

We recognize this is a difficult economy, and therefore perhaps a difficult time to be a development stage company. However, we are enthusiastic about our progress to date and consider our recent channel agreement, in conjunction with our already proven, in production software to be a significant milestone for the Company. I hope shareholders share our enthusiasm and if so, I would ask you spread the word. Everyone knows at least one doctor, so let them know about our products. We are proud of the products we have developed and the security and savings they have brought our clients. digiMedical is a great story, and we have set the foundations for a bright future.

Thank you all for your patience and support.

Best regards,

David W. Lee  
CEO of digiMedical Solutions, Inc.



IMPORTANT \ CONFIDENTIAL:

This correspondence contains information from digiMedical Solutions Corporation that may be privileged, confidential, and exempt from disclosure under applicable laws. If the reader of this message is not the intended recipient or the associate, or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately at our telephone number (817) 503-8880